Biography
Professional Summary
Education & Certifications
- Fellowship: Stanford University Hematology and Oncology Fellowship (1971) CA
- Residency: Stanford University Internal Medicine Residency (1968) CA
- Residency: Barnes and Allied Hospitals/Washington University School of Med (1965) MO
- Internship: Barnes and Allied Hospitals/Washington University School of Med (1964) MO
- Medical Education: George Washington University School of Medicine and Health Sciences (1963) DC
- Board Certification: American Board of Internal Medicine, Hematology (1976)
- Board Certification: American Board of Internal Medicine, Internal Medicine (1970)
- B.A., Johns Hopkins University, Biological Sciences (1959)
- M.D., George Washington U Med School, Medicine (1963)
Honors & Awards
- International Prize for outstanding research in myelodysplastic syndromes (MDS), J.P. McCarthy Foundation (1997)
- Lifetime Achievement Award for MDS, International Workshop for MDS (2022)
Memberships
- Member, American Society of Hematology (1972 - Present)
- Member, Eastern Cooperative Oncology Group, Leukemia Committee (1993 - 2018)
- Chairman, NCCN Myelodysplastic Syndrome Guidelines Panel (1997 - Present)
- Coordinator, International Working Group for Prognosis in MDS (IWG-PM) (2009 - Present)
- Executive Committee, MDS Foundation, Inc (2009 - Present)
- Member, World Health Organization Clinical Advisory Committee for Myeloid Malignancies (2014 - Present)
Administrative Appointments
- Acting Chief, Medical Service, VA Palo Alto Health Care System (1978 - 1979)
- Chair, National Comprehensive Cancer Network Myelodysplastic Syndromes Practice Guidelines Panel (1997 - 2023)
- Coordinator, International Working Group for Prognosis in MDS (2009 - 2023)
- Director, Stanford MDS Center (1998 - 2023)
- Head, Hematology Section, VA Palo Alto Health Care System (1979 - 2005)
- Member, Stanford Scientific Review Committee (2009 - 2023)
Publications
-
Prognostic scoring systems for risk assessment in myelodysplastic syndromes.
Greenberg, P. L., Sanz, G. F., & Sanz, M. A. (1999). Prognostic scoring systems for risk assessment in myelodysplastic syndromes. Forum (Genoa, Italy), 9(1), 17–31. -
Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes
Greenberg, P. (2001). Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes. LANCET, 357(9262), 1059–1060. -
Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines
Greenberg, P. (2001). Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines. ANNALS OF THE RHEUMATIC DISEASES, 60, III41–III42. -
Myelodysplastic syndromes.
Greenberg, P. L., Young, N. S., & Gattermann, N. (2002). Myelodysplastic syndromes. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 136–161. -
-
TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH HEMATOPOIETIC GROWTH-FACTORS
Greenberg, P. L. (1992). TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH HEMATOPOIETIC GROWTH-FACTORS. SEMINARS IN ONCOLOGY, 19(1), 106–114. -
T-CELL SUBSETS AND SUPPRESSOR CELLS IN HUMAN BONE-MARROW
SCHMIDTWOLF, I. G. H., DEJBAKHSHJONES, S., Ginzton, N., Greenberg, P., & Strober, S. (1992). T-CELL SUBSETS AND SUPPRESSOR CELLS IN HUMAN BONE-MARROW. BLOOD, 80(12), 3242–3250. -
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
Greenberg, P. L., Lee, S. J., Advani, R., Tallman, M. S., Sikic, B. I., Letendre, L., … Rowe, J. M. (2004). Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). JOURNAL OF CLINICAL ONCOLOGY, 22(6), 1078–1086. -
Management of patients with higher risk myelodysplastic syndromes
Fukumoto, J. S., & Greenberg, P. L. (2005). Management of patients with higher risk myelodysplastic syndromes. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 56(2), 179–192. -
Myelodysplastic syndromes clinical practice guidelines in oncology.
Greenberg, P. L., Baer, M. R., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., … Tallman, M. S. (2006). Myelodysplastic syndromes clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 4(1), 58–77. -
Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Greenberg, P. L. (2006). Myelodysplastic syndromes: iron overload consequences and current chelating therapies. Journal of the National Comprehensive Cancer Network , 4(1), 91–96. -
HEMATOPOIETIC PROGENITOR-CELL EXPRESSION OF THE H-CAM (CD44) HOMING-ASSOCIATED ADHESION MOLECULE
LEWINSOHN, D. M., Nagler, A., Ginzton, N., Greenberg, P., & BUTCHER, E. C. (1990). HEMATOPOIETIC PROGENITOR-CELL EXPRESSION OF THE H-CAM (CD44) HOMING-ASSOCIATED ADHESION MOLECULE. BLOOD, 75(3), 589–595. -
EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE-MONOCYTE COLONY STIMULATING FACTOR ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES
Nagler, A., Ginzton, N., Negrin, R., Bang, D., Donlon, T., & Greenberg, P. (1990). EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE-MONOCYTE COLONY STIMULATING FACTOR ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES. LEUKEMIA, 4(3), 193–202. -
EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR
Greenberg, P., Negrin, R., Nagler, A., Vincent, M., & Donlon, T. (1990). EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR. Presented at the 2ND INTERNATIONAL CONF ON BLOOD CELL GROWTH FACTORS : THEIR BIOLOGY AND CLINICAL APPLICATIONS, CAPRI,ITALY: ALPHAMED PRESS. -
MAINTENANCE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR
Negrin, R. S., HAEUBER, D. H., Nagler, A., Kobayashi, Y., Sklar, J., Donlon, T., … Greenberg, P. L. (1990). MAINTENANCE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR. BLOOD, 76(1), 36–43. -
EFFECTS OF CSFS IN PRELEUKEMIA
Greenberg, P. L., Negrin, R., & Nagler, A. (1990). EFFECTS OF CSFS IN PRELEUKEMIA. Presented at the 3RD INTERNATIONAL SYMP ON MINIMAL RESIDUAL DISEASE IN ACUTE LEUKEMIA, ROTTERDAM,NETHERLANDS: STOCKTON PRESS. -
IMPACT OF MARROW CYTOGENETICS AND MORPHOLOGY ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES - COMPARISON BETWEEN RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (CSF) AND GRANULOCYTE-MONOCYTE CSF
Nagler, A., Binet, C., MacKichan, M. L., Negrin, R., Bangs, C., Donlon, T., & Greenberg, P. (1990). IMPACT OF MARROW CYTOGENETICS AND MORPHOLOGY ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES - COMPARISON BETWEEN RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (CSF) AND GRANULOCYTE-MONOCYTE CSF. BLOOD, 76(7), 1299–1307. -
FUNCTIONAL INTERACTIONS BETWEEN COLONY-STIMULATING FACTORS AND THE INSULIN FAMILY HORMONES FOR HUMAN MYELOID LEUKEMIC-CELLS
Oksenberg, D., DIECKMANN, B. S., & Greenberg, P. L. (1990). FUNCTIONAL INTERACTIONS BETWEEN COLONY-STIMULATING FACTORS AND THE INSULIN FAMILY HORMONES FOR HUMAN MYELOID LEUKEMIC-CELLS. CANCER RESEARCH, 50(20), 6471–6477. -
TREATMENT OF MYELODYSPLASTIC SYNDROMES
Greenberg, P. L. (1991). TREATMENT OF MYELODYSPLASTIC SYNDROMES. BLOOD REVIEWS, 5(1), 42–50. -
INVITRO MARROW CULTURE STUDIES IN THE MYELODYSPLASTIC SYNDROMES
Greenberg, P. L. (1992). INVITRO MARROW CULTURE STUDIES IN THE MYELODYSPLASTIC SYNDROMES. SEMINARS IN ONCOLOGY, 19(1), 34–46. -
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study
Porter, J., Galanello, R., Saglio, G., Neufeld, E. J., Vichinsky, E., Cappellini, M. D., … Rose, C. (2008). Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. EUROPEAN JOURNAL OF HAEMATOLOGY, 80(2), 168–176. -
-
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Greenberg, P. L., Cosler, L. E., Ferro, S. A., & Lyman, G. H. (2008). The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. Journal of the National Comprehensive Cancer Network , 6(9), 942–953. -
A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes
Gotlib, J., Lavori, P., Quesada, S., Stein, R. S., Shahnia, S., & Greenberg, P. L. (2009). A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. AMERICAN JOURNAL OF HEMATOLOGY, 84(1), 15–20. -
EFFECTS OF INSULIN-LIKE GROWTH-FACTORS ON HEMATOPOIESIS
Greenberg, P. L. (1991). EFFECTS OF INSULIN-LIKE GROWTH-FACTORS ON HEMATOPOIESIS. BLOOD CELLS, 17(2), 344–346. -
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Greenberg, P. L., Sun, Z., Miller, K. B., Bennett, J. M., Tallman, M. S., Dewald, G., … Rowe, J. M. (2009). Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). BLOOD, 114(12), 2393–2400. -
Relationship of differential gene expression profiles in CD34(+) myelodysplastic syndrome marrow cells to disease subtype and progression
Sridhar, K., Ross, D. T., Tibshirani, R., Butte, A. J., & Greenberg, P. L. (2009). Relationship of differential gene expression profiles in CD34(+) myelodysplastic syndrome marrow cells to disease subtype and progression. BLOOD, 114(23), 4847–4858. -
Current therapeutic approaches for patients with myelodysplastic syndromes
Greenberg, P. L. (2010). Current therapeutic approaches for patients with myelodysplastic syndromes. BRITISH JOURNAL OF HAEMATOLOGY, 150(2), 131–143. -
Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes
Greenberg, P. L., Koller, C. A., Cabantchik, Z. I., Warsi, G., Glynos, T., Paley, C., & Schiffer, C. (2010). Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. LEUKEMIA RESEARCH, 34(12), 1560–1565. -
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.
Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., … Westervelt, P. (2011). NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network , 9(1), 30–56. -
BONE-MARROW CELL MODULATION AND INHIBITION OF MYELOPOIESIS BY LARGE GRANULAR LYMPHOCYTES AND NATURAL-KILLER-CELLS
Nagler, A., & Greenberg, P. L. (1990). BONE-MARROW CELL MODULATION AND INHIBITION OF MYELOPOIESIS BY LARGE GRANULAR LYMPHOCYTES AND NATURAL-KILLER-CELLS. INTERNATIONAL JOURNAL OF CELL CLONING, 8(3), 171–183. -
Myelodysplastic Syndromes: Dissecting the Heterogeneity
Greenberg, P. L. (2011). Myelodysplastic Syndromes: Dissecting the Heterogeneity. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1937–1938. -
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na
Seetharam, M., Fan, A. C., Tran, M., Xu, L., Renschler, J. P., Felsher, D. W., … Greenberg, P. L. (2012). Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. LEUKEMIA RESEARCH, 36(1), 98–103. -
Molecular and genetic features of myelodysplastic syndromes
Greenberg, P. L. (2012). Molecular and genetic features of myelodysplastic syndromes. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 34(3), 215–222. -
Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes
Chen, R., Mias, G. I., Li-Pook-Than, J., Jiang, L., Lam, H. Y. K., Chen, R., … Snyder, M. (2012). Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes. CELL, 148(6), 1293–1307. -
Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow
Flores-Figueroa, E., Varma, S., Montgomery, K., Greenberg, P. L., & Gratzinger, D. (2012). Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow. LABORATORY INVESTIGATION, 92(9), 1330–41. -
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F., … Haase, D. (2012). Revised International Prognostic Scoring System for Myelodysplastic Syndromes. BLOOD, 120(12), 2454–2465. -
Reduced rRNA expression and increased rDNA promoter methylation in CD34(+) cells of patients with myelodysplastic syndromes
Raval, A., Sridhar, K. J., Patel, S., Turnbull, B. B., Greenberg, P. L., & Mitchell, B. S. (2012). Reduced rRNA expression and increased rDNA promoter methylation in CD34(+) cells of patients with myelodysplastic syndromes. BLOOD, 120(24), 4812–18. -
-
Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials
Koontz, M. Z., Horning, S. J., Balise, R., Greenberg, P. L., Rosenberg, S. A., Hoppe, R. T., & Advani, R. H. (2013). Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials. JOURNAL OF CLINICAL ONCOLOGY, 31(5), 592–98. -
-
TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR - A PHASE I-II TRIAL
Negrin, R. S., HAEUBER, D. H., Nagler, A., Olds, L. C., Donlon, T., SOUZA, L. M., & Greenberg, P. L. (1989). TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR - A PHASE I-II TRIAL. ANNALS OF INTERNAL MEDICINE, 110(12), 976–84. -
BIOLOGIC NATURE OF THE MYELODYSPLASTIC SYNDROMES
Greenberg, P. L. (1987). BIOLOGIC NATURE OF THE MYELODYSPLASTIC SYNDROMES. ACTA HAEMATOLOGICA, 78, 94–99. -
SELECTIVE GENERATION OF ERYTHROID BURST PROMOTING ACTIVITY BY RECOMBINANT INTERLEUKIN-2 STIMULATED HUMAN LYMPHOCYTES-T AND NATURAL-KILLER CELLS
Skettino, S., Phillips, J., Lanier, L., Nagler, A., & Greenberg, P. (1988). SELECTIVE GENERATION OF ERYTHROID BURST PROMOTING ACTIVITY BY RECOMBINANT INTERLEUKIN-2 STIMULATED HUMAN LYMPHOCYTES-T AND NATURAL-KILLER CELLS. BLOOD, 71(4), 907–914. -
RECEPTOR-BINDING AND MITOGENIC EFFECTS OF INSULIN AND INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II FOR HUMAN MYELOID LEUKEMIC-CELLS
PEPE, M. G., Ginzton, N. H., Lee, P. D. K., Hintz, R. L., & Greenberg, P. L. (1987). RECEPTOR-BINDING AND MITOGENIC EFFECTS OF INSULIN AND INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II FOR HUMAN MYELOID LEUKEMIC-CELLS. JOURNAL OF CELLULAR PHYSIOLOGY, 133(2), 219–227. -
-
EFFECTS OF GRANULOCYTE-COLONY-STIMULATING FACTOR THERAPY ON IN-VITRO HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES
Nagler, A., MacKichan, M. L., Negrin, R. S., Donlon, T., & Greenberg, P. L. (1995). EFFECTS OF GRANULOCYTE-COLONY-STIMULATING FACTOR THERAPY ON IN-VITRO HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES. LEUKEMIA, 9(1), 30–39. -
ENRICHMENT OF BONE-MARROW AND BLOOD PROGENITOR (CD34(+)) CELLS BY DENSITY GRADIENTS WITH SUFFICIENT YIELDS FOR TRANSPLANTATION
Schriber, J. R., DEJBAKHSHJONES, S., KUSNIERZGLAZ, C. R., Ginzton, N., Still, B., Negrin, R. S., … Strober, S. (1995). ENRICHMENT OF BONE-MARROW AND BLOOD PROGENITOR (CD34(+)) CELLS BY DENSITY GRADIENTS WITH SUFFICIENT YIELDS FOR TRANSPLANTATION. EXPERIMENTAL HEMATOLOGY, 23(9), 1024–1029. -
TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN COMBINATION WITH ERYTHROPOIETIN
Negrin, R. S., Stein, R., Vardiman, J., Doherty, K., Cornwell, J., Krantz, S., & Greenberg, P. L. (1993). TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN COMBINATION WITH ERYTHROPOIETIN. BLOOD, 82(3), 737–43. -
MODULATION OF APOPTOSIS IN HUMAN MYELOID LEUKEMIC-CELLS BY GM-CSF
Han, J. H., Gileadi, C., Rajapaksa, R., Kosek, J., & Greenberg, P. L. (1995). MODULATION OF APOPTOSIS IN HUMAN MYELOID LEUKEMIC-CELLS BY GM-CSF. EXPERIMENTAL HEMATOLOGY, 23(3), 265–272. -
Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy
Negrin, R. S., Stein, R., Doherty, K., Cornwell, J., Vardiman, J., Krantz, S., & Greenberg, P. L. (1996). Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy. BLOOD, 87(10), 4076–4081. -
Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes
Greenberg, P. L. (1996). Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes. SEMINARS IN HEMATOLOGY, 33(2), 163–175. -
Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
Rajapaksa, R., Ginzton, N., Rott, L. S., & Greenberg, P. L. (1996). Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. BLOOD, 88(11), 4275–4287. -
GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation
Greenberg, P., Advani, R., Keating, A., Gulati, S. C., Nimer, S., Champlin, R., … Cuffie, C. (1996). GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. BONE MARROW TRANSPLANTATION, 18(6), 1057–1064. -
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LEBEAU, M. M., Fenaux, P., Morel, P., Sanz, G., … Bennett, J. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. BLOOD, 89(6), 2079–2088. -
Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression
Davis, R. E., & Greenberg, P. L. (1998). Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. LEUKEMIA RESEARCH. NASHVILLE,TN,TN,TN,TN,TN,TN,TN,TN,TN,TN,TN: PERGAMON-ELSEVIER SCIENCE LTD. -
Risk factors and their relationship to prognosis in myelodysplastic syndromes
Greenberg, P. L. (1998). Risk factors and their relationship to prognosis in myelodysplastic syndromes. LEUKEMIA RESEARCH, 22, S3–S6. -
-
Programmed cell death (apoptosis) as a mechanism for regulating haematopoietic cell population size
Greenberg, P. L. (1992). Programmed cell death (apoptosis) as a mechanism for regulating haematopoietic cell population size. Focus on Growth Factors, 3(2). -
NCCN Practice Guidelines for Myelodysplastic Syndromes
NCCN Practice Guidelines for Myelodysplastic Syndromes. (1998). Oncology, 12(11A). -
The Myelodysplastic Syndromes .
Greenberg, P. (2000). The Myelodysplastic Syndromes . HEMATOLOGY:BASIC PRINCIPLES AND PRACTICE 3rd Ed., Hoffman R, Benz E, Shattil S, Furie B, Cohen H, Silberstein L, McGlave P, Eds. Churchill Livingstone, NY, -
A Decision Analysis of Allogeneic Bone Marrow Transplantation for the Myelodysplastic Syndromes: Delayed Transplantation for Low Risk Myelodysplasia is Associated with Improved Outcome
A Decision Analysis of Allogeneic Bone Marrow Transplantation for the Myelodysplastic Syndromes: Delayed Transplantation for Low Risk Myelodysplasia is Associated with Improved Outcome. (2004). Blood, 104. -
Novel biospecific agents for the treatment of myelodysplastic syndromes.
Novel biospecific agents for the treatment of myelodysplastic syndromes. (2003). J Nat Comprehensive Cancer Network, 1. -
Myelodysplastic Syndromes: Clinical and Biological Advances
Greenberg, P. L. L. (2006). Myelodysplastic Syndromes: Clinical and Biological Advances. Cambridge University Press, Cambridge, England. -
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. (2006). Blood, 108. -
Phase II Study of Lenalidomide in Transfusion-Dependent, Low and Intermediate-1-Risk Myelodysplastic Syndromes with Normal and Abnormal Karyotypes Other than Deletion 5q.
Phase II Study of Lenalidomide in Transfusion-Dependent, Low and Intermediate-1-Risk Myelodysplastic Syndromes with Normal and Abnormal Karyotypes Other than Deletion 5q. (2008). Blood, 111. -
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-year prospective study.
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-year prospective study. (2008). Eur J Haematol, 80. -
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF. (2008). Blood, 111. -
International MDS Risk Analysis Workshop (IMRAW)/IPSS Re-analyzed: Impact of cytopenias on clinical outcomes in Myelodysplastic Syndrome
Kao, J. M., McMillan, A., & Greenberg, P. L. (2008). International MDS Risk Analysis Workshop (IMRAW)/IPSS Re-analyzed: Impact of cytopenias on clinical outcomes in Myelodysplastic Syndrome. Am J Hematology, 83. -
A phase II study of the farnesyltransferase inhibitor tipifarnib in elderly patients with previously untreated poor-risk acute myeloid leukemia
A phase II study of the farnesyltransferase inhibitor tipifarnib in elderly patients with previously untreated poor-risk acute myeloid leukemia. (2006). Blood, 108. -
Hematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q deletion.
Hematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q deletion. (2006). New Eng J Med, 355. -
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus Statements and Report from a Working Conference
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus Statements and Report from a Working Conference. (2007). Leukemia Research, 31. -
Myelodysplastic Syndromes: Impact of recently analyzed variables for modifying current classification methods
Myelodysplastic Syndromes: Impact of recently analyzed variables for modifying current classification methods. (2007). Clinical Leukemia, 1. -
NCCN Task Force Report: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes
NCCN Task Force Report: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes. (2009). J Nat Comp Cancer Network, 7(Suppl 9). -
Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow
Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow. (2012). Lab Investigation, 92. -
-
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., … Knight, R. (2006). Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. NEW ENGLAND JOURNAL OF MEDICINE, 355(14), 1456–1465. -
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q
Raza, A., Reeves, J. A., Feldman, E. J., Dewald, G. W., Bennett, J. M., Deeg, J., … List, A. F. (2008). Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. BLOOD, 111(1), 86–93. -
PHASE-III RANDOMIZED MULTICENTER TRIAL OF G-CSF VS OBSERVATION FOR MYELODYSPLASTIC SYNDROMES (MDS)
Greenberg, P., Taylor, K., Larson, R., Koeffler, P., Negrin, R., Saba, H., … Brown, S. (1993). PHASE-III RANDOMIZED MULTICENTER TRIAL OF G-CSF VS OBSERVATION FOR MYELODYSPLASTIC SYNDROMES (MDS). BLOOD, 82(10), A196–A196. -
INDUCTION OF HUMAN HEMATOPOIETIC STEM-CELL (CFU-GEMM) GROWTH BY FACTORS RELEASED FROM MITOGEN-STIMULATED SPLEEN-CELLS
Fabian, I., Levitt, L., & Greenberg, P. (1982). INDUCTION OF HUMAN HEMATOPOIETIC STEM-CELL (CFU-GEMM) GROWTH BY FACTORS RELEASED FROM MITOGEN-STIMULATED SPLEEN-CELLS. ELSEVIER SCIENCE INC. -
PURE WHITE-CELL APLASIA - ANTIBODY-MEDIATED AUTOIMMUNE INHIBITION OF GRANULOPOIESIS
Levitt, L. J., Ries, C. A., & Greenberg, P. L. (1983). PURE WHITE-CELL APLASIA - ANTIBODY-MEDIATED AUTOIMMUNE INHIBITION OF GRANULOPOIESIS. NEW ENGLAND JOURNAL OF MEDICINE, 308(19), 1141–46. -
-
Phase it study of Bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS): Preliminary results
Gotlib, J., Jamieson, C. H. M., List, A., Cortes, J., Albitar, M., Sridhar, K., … Greenberg, P. L. (2003). Phase it study of Bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS): Preliminary results. BLOOD, 102(11), 425A–425A. -
A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib)
Fan, A. C., Xu, L., Sridhar, K. J., Tran, M., Banerjee, P., Renschler, J. P., … Felsher, D. W. (2011). A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib). BLOOD, 118(21), 1626–26. -
Phase I/II, randomized, MultiCenter, dose-ascension study of the p38MAPK inhibitor scio469 in patients with myelodysplastic syndrome (MDS).
Sokol, L., Cripe, L., Kantarjian, H., Sekeres, M. A., Parmar, S., Greenberg, P., … List, A. (2006). Phase I/II, randomized, MultiCenter, dose-ascension study of the p38MAPK inhibitor scio469 in patients with myelodysplastic syndrome (MDS). BLOOD, 108(11), 751A–751A. -
LITHIUM TREATMENT IN ADULTS WITH ACUTE MYELOID-LEUKEMIA RECEIVING CHEMOTHERAPY
Horns, R. C., Schrier, S. L., & Greenberg, P. L. (1984). LITHIUM TREATMENT IN ADULTS WITH ACUTE MYELOID-LEUKEMIA RECEIVING CHEMOTHERAPY. MEDICAL AND PEDIATRIC ONCOLOGY, 12(3), 169–172. -
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.
Koreth, J., Pidala, J., Perez, W. S., Deeg, H. J., Garcia-Manero, G., Malcovati, L., … Cutler, C. (2013). Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. Journal of Clinical Oncology , 31(21), 2662–2670. -
The Multifaceted Nature of Myelodysplastic Syndromes: Clinical, Molecular, and Biological Prognostic Features
Greenberg, P. L. (2013). The Multifaceted Nature of Myelodysplastic Syndromes: Clinical, Molecular, and Biological Prognostic Features. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(7), 877–885. -
Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human G-CSF plus erythropoietin: Evidence for in vivo synergy
Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human G-CSF plus erythropoietin: Evidence for in vivo synergy. (1996). Blood, 87. -
Granulopoiesis in acute myeloid leukemia and preleukemia
Granulopoiesis in acute myeloid leukemia and preleukemia. (1971). New Engl J Med, 284. -
-
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS
Barreyro, L., Will, B., Bartholdy, B., Zhou, L., Todorova, T. I., Stanley, R. F., … Steidl, U. (2012). Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. BLOOD, 120(6), 1290–1298. -
Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model
HELLSTROMLINDBERG, E., Negrin, R., Stein, R., Krantz, S., Lindberg, G., Vardiman, J., … Greenberg, P. (1997). Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. BRITISH JOURNAL OF HAEMATOLOGY, 99(2), 344–351. -
MUTATIONS IN THE RAS PROTOONCOGENES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
Neubauer, A., Greenberg, P., Negrin, R., Ginzton, N., & Liu, E. (1994). MUTATIONS IN THE RAS PROTOONCOGENES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES. LEUKEMIA, 8(4), 638–641. -
NCCN Practice Guidelines for chronic myelogenous leukemia
Talpaz, M., Berman, E., Clift, R. A., Copelan, E. A., Emanuel, P. D., Erba, H. P., … Talpaz, M. (2000). NCCN Practice Guidelines for chronic myelogenous leukemia. ONCOLOGY-NEW YORK, 14(11A), 229–240. -
Myelodysplastic Syndromes
Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., Borate, U., De Castro, C. M., … Naganuma, M. (2013). Myelodysplastic Syndromes. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(7), 838–74. -
MYELOPROLIFERATIVE DISORDERS - CORRELATION BETWEEN CLINICAL EVOLUTION AND ALTERATIONS OF GRANULOPOIESIS
Greenberg, P., MARA, B., Bax, I., BROSSEL, R., & Schrier, S. (1976). MYELOPROLIFERATIVE DISORDERS - CORRELATION BETWEEN CLINICAL EVOLUTION AND ALTERATIONS OF GRANULOPOIESIS. AMERICAN JOURNAL OF MEDICINE, 61(6), 878–891. -
MULTIVARIATE-ANALYSIS OF FACTORS ASSOCIATED WITH INVASIVE FUNGAL DISEASE DURING REMISSION INDUCTION THERAPY FOR ACUTE MYELOGENOUS LEUKEMIA
Schwartz, R. S., MacKintosh, F. R., Schrier, S. L., & Greenberg, P. L. (1984). MULTIVARIATE-ANALYSIS OF FACTORS ASSOCIATED WITH INVASIVE FUNGAL DISEASE DURING REMISSION INDUCTION THERAPY FOR ACUTE MYELOGENOUS LEUKEMIA. CANCER, 53(3), 411–419. -
-
-
MULTIVARIATE-ANALYSIS OF FACTORS ASSOCIATED WITH OUTCOME OF TREATMENT FOR ADULTS WITH ACUTE MYELOGENOUS LEUKEMIA
Schwartz, R. S., MacKintosh, F. R., Halpern, J., Schrier, S. L., & Greenberg, P. L. (1984). MULTIVARIATE-ANALYSIS OF FACTORS ASSOCIATED WITH OUTCOME OF TREATMENT FOR ADULTS WITH ACUTE MYELOGENOUS LEUKEMIA. CANCER, 54(8), 1672–1681. -
CLINICAL UTILITY OF INVITRO EVALUATION OF GRANULOPOIESIS
GREENBER, P. L., & Schrier, S. L. (1974). CLINICAL UTILITY OF INVITRO EVALUATION OF GRANULOPOIESIS. ANNUAL REVIEW OF MEDICINE, 25, 269–278. -
SUB-ACUTE MYELOID-LEUKEMIA - CLINICAL REVIEW
Cohen, J. R., CREGER, W. P., Greenberg, P. L., & Schrier, S. L. (1979). SUB-ACUTE MYELOID-LEUKEMIA - CLINICAL REVIEW. AMERICAN JOURNAL OF MEDICINE, 66(6), 959–966. -
-
Myelodysplastic syndromes: clinical practice guidelines in oncology.
Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., Borate, U., De Castro, C. M., … Naganuma, M. (2013). Myelodysplastic syndromes: clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 11(7), 838–874. -
-
Specific plasma autoantibody reactivity in myelodysplastic syndromes
Mias, G. I., Chen, R., Zhang, Y., Sridhar, K., Sharon, D., Xiao, L., … Greenberg, P. L. (2013). Specific plasma autoantibody reactivity in myelodysplastic syndromes. Scientific Reports , 3. -
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes
Zeidan, A. M., Lee, J.-W., Prebet, T., Greenberg, P., Sun, Z., Juckett, M., … Gore, S. D. (2014). Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. BRITISH JOURNAL OF HAEMATOLOGY, 166(3), 352–59. -
Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival.
Johnson, R. C., Kurzer, J. H., Greenberg, P. L., & Gratzinger, D. (2014). Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival. American Journal of Clinical Pathology, 142(6), 795–802. -
-
Mesenchymal Stromal Cell Density is Increased in Higher Grade Myelodysplastic Syndromes and Independently Predicts Survival.
Johnson, R., Kurzer, J., Greenberg, P., & Gratzinger, D. (2014). Mesenchymal Stromal Cell Density is Increased in Higher Grade Myelodysplastic Syndromes and Independently Predicts Survival. . J Clin Path, 142. -
TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR - CLINICAL AND MARROW HEMATOPOIETIC RESPONSES
Greenberg, P., Negrin, R., Nagler, A., & Souza, L. (1990). TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR - CLINICAL AND MARROW HEMATOPOIETIC RESPONSES. Presented at the SYMP ON HEMATOPOIESIS, TAMARRON,CO: WILEY-LISS, INC. -
Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study
Deeg, H. J., Gotlib, J., Beckham, C., Dugan, K., Holmberg, L., Schubert, M., … Greenberg, P. (2002). Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study. LEUKEMIA, 16(2), 162–164. -
MURINE GRANULOPOIESIS AFTER FRACTIONATED TOTAL LYMPHOID IRRADIATION AND ALLOGENEIC BONE-MARROW TRANSPLANTATION
Feiner, R. H., Strober, S., & Greenberg, P. L. (1983). MURINE GRANULOPOIESIS AFTER FRACTIONATED TOTAL LYMPHOID IRRADIATION AND ALLOGENEIC BONE-MARROW TRANSPLANTATION. EXPERIMENTAL HEMATOLOGY, 11(5), 410–417. -
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
Valent, P., Horny, H.-P., Bennett, J. M., Fonatsch, C., Germing, U., Greenberg, P., … Wells, D. A. (2007). Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. LEUKEMIA RESEARCH, 31(6), 727–736. -
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
Park, S., Grabar, S., Kelaidi, C., Beyne-Rauzy, O., Picard, F., Bardet, V., … Dreyfus, F. (2008). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. BLOOD, 111(2), 574–582. -
-
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Schanz, J., Tuechler, H., Sole, F., Mallo, M., Luno, E., Cervera, J., … Haase, D. (2012). New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. JOURNAL OF CLINICAL ONCOLOGY, 30(8), 820–829. -
Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy
Sloand, E. M., Wu, C. O., Greenberg, P., Young, N., & Barrett, J. (2008). Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 2505–2511. -
Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34(+)FISH:results from a German diagnostic study in comparison with an international control group
Braulke, F., Platzbecker, U., Mueller-Thomas, C., Goetze, K., Germing, U., Bruemmendorf, T. H., … Schanz, J. (2015). Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34(+)FISH:results from a German diagnostic study in comparison with an international control group. HAEMATOLOGICA, 100(2), 205–213. -
Monosomal karyotype in MDS: explaining the poor prognosis?
Schanz, J., Tuechler, H., Sole, F., Mallo, M., Luno, E., Cervera, J., … Haase, D. (2013). Monosomal karyotype in MDS: explaining the poor prognosis? LEUKEMIA, 27(10), 1988–1995. -
-
Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
Prebet, T., Sun, Z., Figueroa, M. E., Ketterling, R., Melnick, A., Greenberg, P. L., … Tallman, M. S. (2014). Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. JOURNAL OF CLINICAL ONCOLOGY, 32(12), 1242-? -
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine
Greenberg, P. L., Garcia-Manero, G., Moore, M., Damon, L., Roboz, G., Hu, K., … Franklin, J. (2013). A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. LEUKEMIA & LYMPHOMA, 54(2), 321–328. -
Prognostic factors and scoring systems in myelodysplastic syndromes
Sanz, G. F., Sanz, M. A., & Greenberg, P. L. (1998). Prognostic factors and scoring systems in myelodysplastic syndromes. HAEMATOLOGICA, 83(4), 358–368. -
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
Kantarjian, H. M., Giles, F. J., Greenberg, P. L., Paquette, R. L., Wang, E. S., Gabrilove, J. L., … Berger, D. P. (2010). Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. BLOOD, 116(17), 3163–3170. -
-
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Cheson, B. D., Greenberg, P. L., Bennett, J. M., Lowenberg, B., Wijermans, P. W., Nimer, S. D., … Kantarjian, H. (2006). Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. BLOOD, 108(2), 419–425. -
Synergistic Interactions of Molecular and Clinical Advances for Characterizing the Myelodysplastic Syndromes
Greenberg, P. L. (2015). Synergistic Interactions of Molecular and Clinical Advances for Characterizing the Myelodysplastic Syndromes . J Nat Compr Canc Network , 13(7). -
-
NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes.
Greenberg, P. L., Rigsby, C. K., Stone, R. M., Deeg, H. J., Gore, S. D., Millenson, M. M., … Kumar, R. (2009). NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network , 7, S1–16. -
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
Della Porta, M. G., Tuechler, H., Malcovati, L., Schanz, J., Sanz, G., Garcia-Manero, G., … Cazzola, M. (2015). Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia, 29(7), 1502–1513. -
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy
Silverman, L. R., Greenberg, P., Raza, A., Olnes, M. J., Holland, J. F., Reddy, P., … Wilhelm, F. (2015). Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. HEMATOLOGICAL ONCOLOGY, 33(2), 57–66. -
The anemia of chronic disorders due to renal cell carcinoma: ferrokinetic and morphologic documentation of its surgical correction.
Greenberg, P. L., & CREGER, W. P. (1971). The anemia of chronic disorders due to renal cell carcinoma: ferrokinetic and morphologic documentation of its surgical correction. The American Journal of the Medical Sciences, 261(5), 265–269. -
Cytotoxic effects of cytosine arabinoside and 6-thioguanine in vitro on granulocytic progenitor cells
Greenberg, P. L., VanKersen, I., & Mosny, S. (1976). Cytotoxic effects of cytosine arabinoside and 6-thioguanine in vitro on granulocytic progenitor cells. Cancer Res . -
DENSITY DISTRIBUTION PATTERNS OF MARROW COLONY-FORMING CELLS DURING REMISSION OF ACUTE MYELOGENOUS LEUKEMIA
Heller, P., & Greenberg, P. (1977). DENSITY DISTRIBUTION PATTERNS OF MARROW COLONY-FORMING CELLS DURING REMISSION OF ACUTE MYELOGENOUS LEUKEMIA. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 59(2), 313–316. -
PRELEUKEMIC SYNDROME - CORRELATION OF INVITRO PARAMETERS OF GRANULOPOIESIS WITH CLINICAL-FEATURES
Greenberg, P. L., & MARA, B. (1979). PRELEUKEMIC SYNDROME - CORRELATION OF INVITRO PARAMETERS OF GRANULOPOIESIS WITH CLINICAL-FEATURES. AMERICAN JOURNAL OF MEDICINE, 66(6), 951–958. -
MARROW ADHERENT CELL COLONY-STIMULATING ACTIVITY PRODUCTION IN ACUTE MYELOID-LEUKEMIA
Greenberg, P. L., MARA, B., & Heller, P. (1978). MARROW ADHERENT CELL COLONY-STIMULATING ACTIVITY PRODUCTION IN ACUTE MYELOID-LEUKEMIA. BLOOD, 52(2), 362–378. -
EXPRESSION OF EVI1 IN MYELODYSPLASTIC SYNDROMES AND OTHER HEMATOLOGIC MALIGNANCIES WITHOUT 3Q26 TRANSLOCATIONS
Russell, M., List, A., Greenberg, P., Woodward, S., Glinsmann, B., Parganas, E., … Taetle, R. (1994). EXPRESSION OF EVI1 IN MYELODYSPLASTIC SYNDROMES AND OTHER HEMATOLOGIC MALIGNANCIES WITHOUT 3Q26 TRANSLOCATIONS. BLOOD, 84(4), 1243–1248. -
-
ALTERATION OF COLONY-STIMULATING FACTOR OUTPUT, ENDOTOXEMIA, AND GRANULOPOIESIS IN CYCLIC NEUTROPENIA
Greenberg, P. L., Bax, I., Levin, J., & Andrews, T. M. (1976). ALTERATION OF COLONY-STIMULATING FACTOR OUTPUT, ENDOTOXEMIA, AND GRANULOPOIESIS IN CYCLIC NEUTROPENIA. AMERICAN JOURNAL OF HEMATOLOGY, 1(4), 375–385. -
CORRELATIVE PATTERNS OF LEUKOCYTE COUNTS AT PRESENTATION AND RELAPSE IN ACUTE MYELOGENOUS LEUKEMIA
Schwartz, R. S., MacKintosh, F. R., & Greenberg, P. L. (1986). CORRELATIVE PATTERNS OF LEUKOCYTE COUNTS AT PRESENTATION AND RELAPSE IN ACUTE MYELOGENOUS LEUKEMIA. ACTA HAEMATOLOGICA, 75(2), 79–82. -
STROMAL COLONY-STIMULATING ACTIVITY PRODUCTION AND MYELOID COLONY-FORMING CELLS IN HUMAN HEMATOPOIETIC AND NON-HEMATOPOIETIC BONE-MARROW
Schwartz, R. S., & Greenberg, P. L. (1981). STROMAL COLONY-STIMULATING ACTIVITY PRODUCTION AND MYELOID COLONY-FORMING CELLS IN HUMAN HEMATOPOIETIC AND NON-HEMATOPOIETIC BONE-MARROW. BLOOD, 57(4), 771–780. -
CYTOTOXIC EFFECTS OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE AND 6-THIOGUANINE INVITRO ON GRANULOCYTIC PROGENITOR CELLS
Greenberg, P. L., VANKERSEN, I., & MOSNY, S. (1976). CYTOTOXIC EFFECTS OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE AND 6-THIOGUANINE INVITRO ON GRANULOCYTIC PROGENITOR CELLS. CANCER RESEARCH, 36(12), 4412–4417. -
CYTOTOXIC EFFECTS OF INTERFERON INVITRO ON GRANULOCYTIC PROGENITOR CELLS
Greenberg, P. L., & MOSNY, S. A. (1977). CYTOTOXIC EFFECTS OF INTERFERON INVITRO ON GRANULOCYTIC PROGENITOR CELLS. CANCER RESEARCH, 37(6), 1794–1799. -
SPLENIC GRANULOCYTOPOIESIS AND PRODUCTION OF COLONY-STIMULATING ACTIVITY IN LYMPHOMA AND LEUKEMIA
Greenberg, P. L., & STEED, S. M. (1981). SPLENIC GRANULOCYTOPOIESIS AND PRODUCTION OF COLONY-STIMULATING ACTIVITY IN LYMPHOMA AND LEUKEMIA. BLOOD, 57(1), 119–129. -
CLINICAL RELEVANCE OF INVITRO STUDY OF GRANULOCYTOPOIESIS
Greenberg, P. L. (1980). CLINICAL RELEVANCE OF INVITRO STUDY OF GRANULOCYTOPOIESIS. SCANDINAVIAN JOURNAL OF HAEMATOLOGY, 25(5), 369–381. -
CHARACTERIZATION OF ANTIGENIC DETERMINANTS ON HUMAN MYELOID COLONY-FORMING CELLS WITH MONOCLONAL-ANTIBODIES
Greenberg, P., Grossman, M., Charron, D., & Levy, R. (1981). CHARACTERIZATION OF ANTIGENIC DETERMINANTS ON HUMAN MYELOID COLONY-FORMING CELLS WITH MONOCLONAL-ANTIBODIES. EXPERIMENTAL HEMATOLOGY, 9(7), 781–787. -
THE SMOLDERING MYELOID LEUKEMIC STATES - CLINICAL AND BIOLOGIC FEATURES
Greenberg, P. L. (1983). THE SMOLDERING MYELOID LEUKEMIC STATES - CLINICAL AND BIOLOGIC FEATURES. BLOOD, 61(6), 1035–1044. -
RESPONSE OF AGRANULOCYTOSIS TO PROLONGED ANTI-THYMOCYTE GLOBULIN THERAPY
CHUDWIN, D. S., Cowan, M. J., Greenberg, P. L., Wara, D. W., & Ammann, A. J. (1983). RESPONSE OF AGRANULOCYTOSIS TO PROLONGED ANTI-THYMOCYTE GLOBULIN THERAPY. JOURNAL OF PEDIATRICS, 103(2), 223–227. -
HUMAN SPLEEN-CELL GENERATION OF FACTORS STIMULATING HUMAN PLURIPOTENT STEM-CELL, ERYTHROID, AND MYELOID PROGENITOR-CELL GROWTH
Fabian, I., Douer, D., Levitt, L., Kletter, Y., & Greenberg, P. L. (1985). HUMAN SPLEEN-CELL GENERATION OF FACTORS STIMULATING HUMAN PLURIPOTENT STEM-CELL, ERYTHROID, AND MYELOID PROGENITOR-CELL GROWTH. BLOOD, 65(4), 990–996. -
13-CIS RETINOIC ACID TREATMENT FOR MYELODYSPLASTIC SYNDROMES
Picozzi, V. J., SWANSON, G. F., Morgan, R., Hecht, F., & Greenberg, P. L. (1986). 13-CIS RETINOIC ACID TREATMENT FOR MYELODYSPLASTIC SYNDROMES. JOURNAL OF CLINICAL ONCOLOGY, 4(4), 589–595. -
RESPONSES OF HEMATOPOIETIC PRECURSORS TO 13-CIS RETINOIC ACID AND 1,25 DIHYDROXYVITAMIN-D3 IN THE MYELODYSPLASTIC SYNDROMES
Swanson, G., Picozzi, V., Morgan, R., Hecht, F., & Greenberg, P. (1986). RESPONSES OF HEMATOPOIETIC PRECURSORS TO 13-CIS RETINOIC ACID AND 1,25 DIHYDROXYVITAMIN-D3 IN THE MYELODYSPLASTIC SYNDROMES. BLOOD, 67(4), 1154–1161. -
BIOLOGIC ABNORMALITIES IN THE MYELODYSPLASTIC SYNDROMES AND MYELOPROLIFERATIVE DISORDERS
Greenberg, P. L. (1986). BIOLOGIC ABNORMALITIES IN THE MYELODYSPLASTIC SYNDROMES AND MYELOPROLIFERATIVE DISORDERS. ACTA HAEMATOLOGICA JAPONICA, 49(8), 1509–1527. -
CHARACTERIZATION OF THE INVITRO STROMAL MICROENVIRONMENT OF HUMAN-BONE MARROW
Strobel, E. S., GAY, R. E., & Greenberg, P. L. (1986). CHARACTERIZATION OF THE INVITRO STROMAL MICROENVIRONMENT OF HUMAN-BONE MARROW. INTERNATIONAL JOURNAL OF CELL CLONING, 4(5), 341–356. -
ROLE OF INTRACELLULAR DEGRADATION OF EPIDERMAL GROWTH-FACTOR IN MITOGENESIS
Greenberg, P. L., & ROZENGURT, E. (1982). ROLE OF INTRACELLULAR DEGRADATION OF EPIDERMAL GROWTH-FACTOR IN MITOGENESIS. EXPERIMENTAL CELL RESEARCH, 142(1), 111–117. -
Chronic myelogenous leukemia.
O'Brien, S., Berman, E., Bhalla, K., Copelan, E. A., Devetten, M. P., Emanuel, P. D., … Wetzler, M. (2005). Chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network , 3(6), 732–755. -
Intramedullary influences on in vitro granulopoiesis in human acute myeloid leukemia.
Greenberg, P., & MARA, B. (1979). Intramedullary influences on in vitro granulopoiesis in human acute myeloid leukemia. Haematology and Blood Transfusion, 23, 199–204. -
Chronic myelogenous leukemia.
O'Brien, S., Berman, E., Bhalla, K., Copelan, E. A., Devetten, M. P., Emanuel, P. D., … Wetzler, M. (2007). Chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network , 5(5), 474–496. -
-
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
Maxson, J. E., Luty, S. B., Macmaniman, J. D., Paik, J. C., Gotlib, J., Greenberg, P., … Tyner, J. W. (2016). The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. Clinical Cancer Research , 22(3), 757–764. -
Frequency of del(12p) is Commonly Underestimated in Myelodysplastic Syndromes: Results from a German Diagnostic Study in Comparison with an International Control Group
Braulke, F., Mueller-Thomas, C., Goetze, K., Platzbecker, U., Germing, U., Hofmann, W.-K., … Schanz, J. (2015). Frequency of del(12p) is Commonly Underestimated in Myelodysplastic Syndromes: Results from a German Diagnostic Study in Comparison with an International Control Group. GENES CHROMOSOMES & CANCER, 54(12), 809–817. -
Update on Myelodysplastic Syndromes Classification and Prognosis.
Gratzinger, D., & Greenberg, P. L. (2013). Update on Myelodysplastic Syndromes Classification and Prognosis. Surgical Pathology Clinics, 6(4), 693–728. -
-
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Prebet, T., Sun, Z., Ketterling, R. P., Zeidan, A., Greenberg, P., Herman, J., … Gore, S. D. (2016). Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. British Journal of Haematology, 172(3), 384–391. -
Immune checkpoint pathways: perspectives on myeloid malignancies
Rivera, G. A., Behbahan, I. S., & Greenberg, P. L. (2016). Immune checkpoint pathways: perspectives on myeloid malignancies. LEUKEMIA & LYMPHOMA, 57(5), 995–1001. -
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., … Silverman, L. R. (2016). Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. LANCET ONCOLOGY, 17(4), 496–508. -
-
Time-dependent changes in mortality and transformation risk in MDS.
Pfeilstöcker, M., Tuechler, H., Sanz, G., Schanz, J., Garcia-Manero, G., Solé, F., … Greenberg, P. L. (2016). Time-dependent changes in mortality and transformation risk in MDS. Blood, 128(7), 902–910. -
-
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., … Haase, D. (2016). Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood. -
Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis
Park, S., Fenaux, P., Greenberg, P., Mehta, B., Callaghan, F., Kim, C., … Xu, H. (2016). Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis. BRITISH JOURNAL OF HAEMATOLOGY, 174(5), 730–747. -
-
ABNORMAL INVITRO CLONAL GROWTH-PATTERNS IN THE MYELODYSPLASTIC SYNDROMES AND OTHER HEMATOLOGIC MALIGNANCIES - RESPONSES TO RETINOIC ACID AND VITAMIN-D
Greenberg, P. (1986). ABNORMAL INVITRO CLONAL GROWTH-PATTERNS IN THE MYELODYSPLASTIC SYNDROMES AND OTHER HEMATOLOGIC MALIGNANCIES - RESPONSES TO RETINOIC ACID AND VITAMIN-D. ACTA HAEMATOLOGICA JAPONICA, 49(2), 181–181. -
THE ROLE OF HEMATOPOIETIC GROWTH-FACTORS IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
Greenberg, P. (1995). THE ROLE OF HEMATOPOIETIC GROWTH-FACTORS IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES. GEMATOLOGIYA I TRANSFUZIOLOGIYA, 40(2), 12–13. -
-
Myelodysplastic Syndromes, Version 2.2017 Clinical Practice Guidelines in Oncology
Greenberg, P. L., Stone, R. M., Al-Kali, A., Barta, S. K., Bejar, R., Bennett, J. M., … Smith, C. (2017). Myelodysplastic Syndromes, Version 2.2017 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(1), 60–87. -
-
-
-
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
Tefferi, A., Rajkumar, S. V., Gertz, M. A., Kyle, R. A., Kantarjian, H., Allison, J., … Wiernik, P. H. (2015). In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. MAYO CLINIC PROCEEDINGS, 90(8), 996–1000. -
-
-
-
-
-
-
-
Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib.
Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., Gaidano, G., … Garcia-Manero, G. (2015). Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients.
Silverman, L. R., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., … Garcia-Manero, G. (2015). Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
-
Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs)
Silverman, L. R., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., … Garcia-Manero, G. (2014). Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs). BLOOD. AMER SOC HEMATOLOGY. -
-
Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., … Silverman, L. R. (2014). Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs). BLOOD. AMER SOC HEMATOLOGY. -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine
Greenberg, P. L., Garcia-Manero, G., Moore, M. R., Damon, L. E., Roboz, G. J., Wei, H., … Franklin, J. L. (2009). Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine. BLOOD. AMER SOC HEMATOLOGY. -
-
-
-
-
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance
Schanz, J., Sole, F., Mallo, M., Luno, E., Cervera, J., Granada, I., … Haase, D. (2018). Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. GENES CHROMOSOMES & CANCER, 57(11), 547–56. -
-
-
A two-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
Raponi, M., Lancet, J. E., Fan, H., Dossey, L., Lee, G., Gojo, I., … Karp, J. E. (2007). A two-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. BLOOD. AMER SOC HEMATOLOGY. -
Treatment of poor prognosis AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC).
Advani, R., Saba, H. I., Tallman, M., Rowe, J. M., Wiernik, P. H., Ramek, J., … Greenberg, P. (1997). Treatment of poor prognosis AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC). BLOOD, 90(10), 2260. -
GRANULOCYTE DIFFERENTIATION FACTOR PRODUCTION BY HUMAN MARROW AND BLOOD-CELLS
GREENBERG, P. L., BAKER, S. J., FOK, W. Y., FOUNG, S. K., & ENGLEMAN, E. G. (1984). GRANULOCYTE DIFFERENTIATION FACTOR PRODUCTION BY HUMAN MARROW AND BLOOD-CELLS. EXPERIMENTAL HEMATOLOGY, 12(6), 370. -
-
-
-
-
-
-
-
-
Phase I/II study of tipifarnib (ZARNESTRA (TM), farnesyltransferase inhibitor [FTI] R115777) in patients with myeloproliferative disorders (MPDs): Interim results.
Gotlib, J., Loh, M., Lancet, J. E., Vattikuti, S., Quesada, S., Dugan, K., … Greenberg, P. L. (2003). Phase I/II study of tipifarnib (ZARNESTRA (TM), farnesyltransferase inhibitor [FTI] R115777) in patients with myeloproliferative disorders (MPDs): Interim results. BLOOD. AMER SOC HEMATOLOGY. -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker, U., Wong, R. S., Verma, A., Abboud, C., Araujo, S., Chiou, T.-J. J., … Giagounidis, A. (2015). Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. The Lancet. Haematology, 2(10), e417–26. -
Granulocyte-monocyte and Granulocyte-Colony Stimulating Factors in Myelodysplastic Syndromes.
Nagler, A., & Greenberg, P. L. (1991). Granulocyte-monocyte and Granulocyte-Colony Stimulating Factors in Myelodysplastic Syndromes. Leukemia & Lymphoma, 5(4), 219–30. -
-
-
-
-
-
-
-
PROPOSAL OF A NEW, COMPREHENSIVE CYTOGENETIC SCORING SYSTEM FOR PRIMARY MDS
Schanz, J., Tuechler, H., Sole, F., Mallo, M., Hildebrandt, B., Slovak, M., … Haase, D. (2010). PROPOSAL OF A NEW, COMPREHENSIVE CYTOGENETIC SCORING SYSTEM FOR PRIMARY MDS. HAEMATOLOGICA, 95, 219. -
CHRONICALLY TRANSFUSED MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS HAVE SEVERE IRON BURDEN: DEFERASIROX TREATMENT REDUCES IRON OVERLOAD AND IMPROVES LIVER FUNCTION
Gattermann, N., Greenberg, P., Urabe, A., Habr, D., Kpamegan, E., & Porter, J. (2012). CHRONICALLY TRANSFUSED MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS HAVE SEVERE IRON BURDEN: DEFERASIROX TREATMENT REDUCES IRON OVERLOAD AND IMPROVES LIVER FUNCTION. HAEMATOLOGICA, 97, 138. -
Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study.
Atallah, E., Logan, B., Chen, M., Cutler, C., Deeg, J., Jacoby, M., … Rizzo, J. D. (2019). Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. JAMA Oncology. -
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux, P., Platzbecker, U., Mufti, G. J., Garcia-Manero, G., Buckstein, R., Santini, V., … List, A. F. (2020). Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. The New England Journal of Medicine, 382(2), 140–51. -
Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation.
Behbehani, G. K., Finck, R., Samusik, N., Sridhar, K., Fantl, W. J., Greenberg, P. L., & Nolan, G. P. (2020). Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation. Cytometry. Part B, Clinical Cytometry. -
Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey.
Pine, A. B., Chokr, N., Stahl, M., Steensma, D. P., Sekeres, M. A., Litzow, M. R., … Zeidan, A. M. (2020). Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leukemia & Lymphoma, 1–10. -
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
Angelucci, E., Li, J., Greenberg, P., Wu, D., Hou, M., Montano Figueroa, E. H., … Garcia-Manero, G. (2020). Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. Annals of Internal Medicine. -
SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM).
Malcovati, L., Stevenson, K., Papaemmanuil, E., Neuberg, D., Bejar, R., Boultwood, J., … Cazzola, M. (2020). SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). Blood. -
Myelodysplastic syndromes: moving towards personalized management.
Hellström-Lindberg, E., Tobiasson, M., & Greenberg, P. (2020). Myelodysplastic syndromes: moving towards personalized management. Haematologica. -
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
Azizi, A., Ediriwickrema, A., Dutta, R., Patel, S. A., Shomali, W., Medeiros, B., … Zhang, T. (2020). Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leukemia & Lymphoma, 1–8. -
Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms.
Spinner, M. A., Aleshin, A., Santaguida, M. T., Schaffert, S. A., Zehnder, J. L., Patterson, A. S., … Greenberg, P. L. (2020). Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms. Blood Advances, 4(12), 2768–78. -
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R. S., Sekeres, M. A., … Sanz, G. (2020). Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia. -
Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations.
Feurstein, S., Adegunsoye, A., Mojsilovic, D., Vij, R., West DePersia, A. H., Rajagopal, P. S., … Churpek, J. E. (2020). Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Advances, 4(19), 4873–86. -
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., … Papaemmanuil, E. (2021). Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020). NATURE MEDICINE. -
A Retrospective Analysis From Patients Treated in The MEDALIST Study: Safety and Efficacy Of Luspatercept Treatment In Patients With Myelodysplastic Syndrome/Myeloproliferative Neoplasm With Ring Sideroblasts And Thrombocytosis
Komrokji, R. S., Platzbecker, U., Fenaux, P., Garcia-Manero, G., Mufti, G. J., Santini, V., … Verma, A. (2021). A Retrospective Analysis From Patients Treated in The MEDALIST Study: Safety and Efficacy Of Luspatercept Treatment In Patients With Myelodysplastic Syndrome/Myeloproliferative Neoplasm With Ring Sideroblasts And Thrombocytosis. BRITISH JOURNAL OF HAEMATOLOGY, 193, 67–68. -
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
Steensma, D. P., Wermke, M., Klimek, V. M., Greenberg, P. L., Font, P., Komrokji, R. S., … Platzbecker, U. (2021). Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. -
Metchnikoff's inflamed legacy: the dysplastic nature of myelodysplastic syndrome's innate Immunity.
Greenberg, P. L. (2021). Metchnikoff's inflamed legacy: the dysplastic nature of myelodysplastic syndrome's innate Immunity. Haematologica. -
COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R., Sekeres, M., … Sanz, G. (2021). COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS). LEUKEMIA RESEARCH. PERGAMON-ELSEVIER SCIENCE LTD. -
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.
Gerds, A. T., Scott, B. L., Greenberg, P. L., Lin, T. L., Pollyea, D. A., Verma, A. K., … Donnellan, W. B. (1800). Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. Blood Advances. -
NCCN Guidelines Insights: Myelodysplastic Syndromes, Version 3.2022.
Greenberg, P. L., Stone, R. M., Al-Kali, A., Bennett, J. M., Borate, U., Brunner, A. M., … Hochstetler, C. (2022). NCCN Guidelines Insights: Myelodysplastic Syndromes, Version 3.2022. Journal of the National Comprehensive Cancer Network : JNCCN, 20(2), 106–117. -
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Komrokji, R. S., Platzbecker, U., Fenaux, P., Zeidan, A. M., Garcia-Manero, G., Mufti, G. J., … Verma, A. (2022). Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia. -
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.
Zeidan, A. M., Platzbecker, U., Garcia-Manero, G., Sekeres, M. A., Fenaux, P., DeZern, A. E., … Komrokji, R. S. (2022). Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. Blood. -
MDS and MDS/MPN Genomic Subgroups Demonstrate Differential E x Vivo Drug Sensitivity
Spinner, M. A., Schaffert, S. A., Stehr, H., TSantaguida, M., Kita, R., Aleshin, A., … Greenberg, P. L. (2021). MDS and MDS/MPN Genomic Subgroups Demonstrate Differential E x Vivo Drug Sensitivity. BLOOD. AMER SOC HEMATOLOGY. -
An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS).
Stahl, M., Abdel-Wahab, O., Wei, A. H., Savona, M. R., Xu, M. L., Xie, Z., … Zeidan, A. M. (2022). An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS). Blood Advances. -
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
Zeidan, A. M., Bewersdorf, J. P., Buckstein, R., Sekeres, M. A., Steensma, D. P., Platzbecker, U., … Santini, V. (2022). Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia. -
Recent Clinical and Molecular Advances for the Classification of Myelodysplastic Neoplasms.
DeZern, A. E., & Greenberg, P. L. (2022). Recent Clinical and Molecular Advances for the Classification of Myelodysplastic Neoplasms. Journal of the National Comprehensive Cancer Network : JNCCN, 20(12), 1280–1283. -
Myelodysplastic syndromes, thy name is heterogeneity.
Greenberg, P. L. (2023). Myelodysplastic syndromes, thy name is heterogeneity. British Journal of Haematology. -
Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories
Pfeilstocker, M., Tuechler, H., Ades, L., Cermak, J., Chermat, F., Della Porta, M. G., … Greenberg, P. L. (2022). Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories. BLOOD. AMER SOC HEMATOLOGY. -
Correlation of Mutational Profiles and Cytogenetics with Morphologic Dysplasia in Myelodysplastic Syndromes
Kumar, J., Khanna, V., Lu, R., Stehr, H., Spinner, M. A., Silva, O., … Tan, B. (2022). Correlation of Mutational Profiles and Cytogenetics with Morphologic Dysplasia in Myelodysplastic Syndromes. BLOOD. AMER SOC HEMATOLOGY. -
Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
Sirenko, M., Bernard, E., Beck, D. B., Creignou, M., Domenico, D., Farina, A., … Papaemmanuil, E. (2022). Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS. BLOOD. AMER SOC HEMATOLOGY. -
A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R., Sekeres, M., … Sanz, G. (2023). A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS). LEUKEMIA RESEARCH. PERGAMON-ELSEVIER SCIENCE LTD. -
ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS - AN ANALYSIS OF THE IWG-PM DATABASE
Pfeilstoecker, M., Tuechler, H., Ades, L., Cermak, J., Chermat, F., Della Porta, M., … Greenberg, P. (2023). ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS - AN ANALYSIS OF THE IWG-PM DATABASE. LEUKEMIA RESEARCH. PERGAMON-ELSEVIER SCIENCE LTD. -
GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
Bernard, E., Hasserjian, R., Greenberg, P., Ossa, J. A., Creignou, M., Nannya, Y., … Papaemmanuil, E. (2023). GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES. LEUKEMIA RESEARCH. PERGAMON-ELSEVIER SCIENCE LTD. -
Prognostication and risk stratification of patients with myelodysplastic syndromes.
DeZern, A., & Greenberg, P. L. (2023). Prognostication and risk stratification of patients with myelodysplastic syndromes. Blood. -
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl, M., Bewersdorf, J. P., Xie, Z., Porta, M. G., Komrokji, R., Xu, M. L., … Zeidan, A. M. (2023). Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Reviews, 101128. -
SIRT7 IMPROVES HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROME THROUGH REGULATING MITOCHONDRIAL STRESS
Wang, Y., Maruichi, A., song, Z., Greenberg, P., & Chen, D. (2023). SIRT7 IMPROVES HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROME THROUGH REGULATING MITOCHONDRIAL STRESS. EXPERIMENTAL HEMATOLOGY. ELSEVIER SCIENCE INC. -
The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
Khanna, V., Lu, R., Kumar, J., Molina, A., Stehr, H., Spiteri, E., … Greenberg, P. L. (2023). The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms. Leukemia Research, 136, 107433. -
How we reduce and treat post-transplant relapse of MDS.
Mina, A., Greenberg, P. L., & Deeg, H. J. (2024). How we reduce and treat post-transplant relapse of MDS. Blood. -
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Bernard, E., Tuechler, H., Greenberg, P. L., Hasserjian, R. P., Arango Ossa, J. E., Nannya, Y., … Papaemmanuil, E. (2022). Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evidence, 1(7), EVIDoa2200008. -
Shared and distinct mechanisms of UBA1 inactivation across different diseases.
Collins, J. C., Magaziner, S. J., English, M., Hassan, B., Chen, X., Balanda, N., … Werner, A. (2024). Shared and distinct mechanisms of UBA1 inactivation across different diseases. The EMBO Journal. -
UBA1 Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes
Sirenko, M., Bernard, E., Creignou, M., Domenico, D., Farina, A., Ossa, J. E. A., … Papaemmanuil, E. (2023). UBA1 Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes. BLOOD. AMER SOC HEMATOLOGY. -
Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications
Bernard, E., Hasserjian, R., Greenberg, P. L., Ossa, J. E. A., Creignou, M., Nannya, Y., … Papaemmanuil, E. (2023). Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications. BLOOD. AMER SOC HEMATOLOGY. -
Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study
Garcia-Manero, G., Ooi, M., Lao, Z., Gill, H., Abaza, Y., Stahl, M., … Woo, J. (2023). Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study. BLOOD. AMER SOC HEMATOLOGY. -
p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.
Brar, N., Lawrence, L., Fung, E., Zehnder, J. L., Greenberg, P. L., Mannis, G. N., … Fernandez-Pol, S. (2024). p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes. American Journal of Clinical Pathology.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases »
- Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia »
- Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk »
- Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders »
- Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk »
- Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders »
- Bevacizumab in Treating Patients With Myelodysplastic Syndrome »
- Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk »
- Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden »
- Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) »
Practice Locations
Hematologic Cancer Program Palo Alto, CA
Palo Alto, CAHematologic Cancer Program
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Patient Reviews
(80 reviews)
View More »
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology orders
- View referral status
- Access medical records